The pharmaceuticals and healthcare business is one of the most important businesses in CGE. The business covers a number of different areas, including synthetic small molecule pharmaceuticals, biologics, biotransformations, genetic engineering, traditional Chinese medicines (finished dosage forms, Chinese herbal materials), pharmaceutical whole sale and distribution, retail drugstore chain, etc.

After years of development China Grand pharmaceutical and healthcare business has established four major advanced industrial platforms including fermentation, synthetic chemistry, modern traditional Chinese medicine and protein-based biopharmaceuticals.

Fermentation industrial platform: Huadong Medicine Co., Ltd. plays a leading role in fermentation-based pharmaceutical production in China Grand Pharmaceutical group. The production bases are located in multiple places including Hangzhou, Ningbo, Xi’an, Yancheng, and other places. Huadong Medicine Co., Ltd., a nationally-renowned pharmaceutical group, has been a modern and comprehensive pharmaceutical group engaged in R&D, production, marketing, wholesale and distribution businesses. The company’s main products cover several major therapeutic areas including autoimmune diseases, gastrointestinal diseases, diabetes, cardiovascular disease and analgesic. These products are manufactured for both domestic and international markets. The company also has large wholesale and distribution business for traditional Chinese medicines, western medicines, medical devices, chemicals, glassware and other products.

Synthetic chemistry-based industrial platform: Grand Pharma (China) Co., Ltd. plays a leading role in synthetic chemistry-based pharmaceutical production in China Grand Pharmaceutical Group. This industrial platform is mainly engaged in the production of finished drugs for the treatment of ophthalmic and cardiovascular diseases, and the production of amino acids, steroid hormone and active pharmaceutical ingredients (APIs). The products of the company cover a wide range of categories including pharmaceutical intermediates, APIs, traditional Chinese medicines, biopharmaceuticals, various finished drug products, food additives, etc. These products are marketed in dozens of countries and regions in Asia, Europe and America. Major manufacturing bases are located in multiple places including Wuhan, Huangshi, Xianju, Yancheng and Baoding.

The industrial platform of Modern Tradition Chinese Medicine: This industrial platform in China Grand Pharmaceutical Group is led by Lei Yunshang Pharmaceutical Group, which has a nearly 300-year history engaged in the production of traditional Chinese medicines. A unified brand name of “Lei Yunshang” is used by the production bases established in Suzhou, Changshu, Shenyang, Changchun, Yunfu, Kunming and other places. Multiple products of the company have the status of ‘state-classified formula’ or ‘state-protected Traditional Chinese Medicine’. Finished drug products produced by the company are mainly used in the therapeutic areas of oncology, cardiovascular disease, liver and kidney diseases.

Currently with Lei Yunshang Pharmaceutical Group as the leader, this industrial platform has developed into a large and comprehensive pharmaceutical group of traditional Chinese medicine with a fully integrated industrial chain engaged in R&D, production and marketing and sales of traditional and modern Chinese medicines for a wide range of therapeutic areas.

Biopharmaceutical platform: This industrial platform led by Sichuan Grand Shuyang Pharmaceutical Co., Ltd. mainly produces blood plasma-based medicines, vaccines and recombinant biopharmaceutical products, with its production and R&D bases located in Chengdu, Zhengzhou and Hangzhou. As one of the earliest state-designated blood product manufacturers and one of the largest domestic blood product manufacturers, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. has developed into an important blood products production base in China.

CGE Pharmaceutical and healthcare businesses will continue to follow the path of achieving sustainable development through continuous innovation. Viewing R&D as having strategic importance, the business group continues to invest a large amount of funds in specific areas. Multiple approaches through the building-up of internal R&D capacity, establishing alliances with academic institutions and international collaborations have resulted in the successful development and launch of many new products in recent years. China Grand Pharmaceutical Group now has a total of 316 products that either have patent protections, or have new drug certifications, or belong to state-classified formula or state-protected Traditional Chinese Medicines. China Grand Pharmaceutical Group has established marketing and distribution networks domestically and across the globe, and has built a marketing and sales team of more than 10,000 people. Domestically, marketing teams in various specific fields have established extensive partnerships with over 10,000 grade-two hospitals, 40,000 grass-roots medical institutions and Top 100 chain drugstores. CGE has built a comprehensive business model in its pharmaceuticals and healthcare industry that integrates R&D, production and marketing and distribution into one with a combination of traditional Chinese and Western medicines, and domestic and global market focuses.

CGE pharmaceutical and healthcare business places top priority in product quality control. The group now has a number of Famous Trademarks of China such as “Corbrin” and “Lei Yunshang”, and a number of Famous Provincial Trademarks such as “Xin Saisiping”, “Ka Boping”, “Shu Yang”, “Bai Neiping” and “Fu Chi”, and a China Time-Honored Brand “Lei Yunshang”. The subsidiary companies in China Grand Pharmaceutical Group have been awarded multiple times with a number of awards such as “National Wuyi Labor Awards”, “National High-Tech Enterprises”, “Top 500 Manufacturing Enterprises of China”, “Provincial Patent Model Enterprises”, “Provincial AAA Credit Enterprises”, “Credible Enterprises for Ten Consecutive Years”, “Industrial and Commercial Star Enterprises”.

To keep up with an accelerated pace of China’s reform on medical and healthcare system and under the corporate guidance of “Loyalty, Sincerity, Diligence and Innovation”, the pharmaceutical and healthcare business of CGE will continue to pursue the strategy of keeping high product quality to maintain enterprise lifeline, making innovation for further development and always maintaining “Serving Society” as the ultimate corporate mission to continuously contribute to the society.